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Abstract Prop-1 is a newly isolated pituitary-specific paired-
like homeodomain transcription factor whose cDNA sequence is
well known in mouse. To study its involvement in human
combined pituitary hormone deficiency (CPHD), we have
isolated the human cDNA ortholog and determined the exon/
intron organization and chromosomal localization of the human
gene. A Prop-1 defect was characterized in three CPHD
families. One missense mutation (R73C) involves a residue
conserved in 95% of the more than 400 homeodomain proteins so
far identified ; in vitro splicing assays demonstrated the
functional importance of the second defect, whereas the
remaining mutation is a frameshift. Given the disease phenotype
documented in the patients, these data, which will facilitate
molecular investigations in other patients, demonstrate the
crucial role of Prop-1 in the proper development of somato-
trophs, lactotrophs, thyreotrophs and gonadotrophs.
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1. Introduction
Short stature of genetic origin due to growth hormone de-
¢ciency (GHD) is a highly heterogeneous condition, at the
clinical, biological and genetic level [1] ; the GHD phenotype
can be either isolated (IGHD) or associated with combined
pituitary hormone de¢ciency (CPHD). In the latter case, the
patients’ phenotype is characterized by a de¢ciency of one or
more of the other hormones produced by the anterior pitui-
tary, i.e. prolactin, thyroid-stimulating hormone L (TSHL),
luteinizing and follicle stimulating hormones (LH and FSH),
or adrenocorticotrophic hormone, produced by lactotrophs,
thyreotrophs, gonadotrophs, or corticotrophs, respectively.
Although the great majority of IGHD or CPHD cases are
sporadic, familial cases have also been described, the disease
phenotype being transmitted as an autosomal or X-linked
trait [1].
The study of naturally occurring mouse mutants displaying
a CPHD phenotype demonstrated both allelic and locus het-
erogeneity in this condition: the dwarf phenotype of two
mouse strains, named Snell and Jackson, with CPHD charac-
terized by absent GH, prolactin and TSHL gene expression
associated with pituitary hypoplasia, is due to mutations in
the Pit-1 gene [2]. The corresponding protein, a member of the
POU family of transcription factors, is involved in transcrip-
tional activation of GH, prolactin, and TSHL genes and in the
di¡erentiation and proliferation of somatotrophs, lactotrophs,
and thyreotrophs [2]. Strikingly, a similar but not identical
dwarf phenotype has been identi¢ed in a third murine strain,
named Ames, in which the de¢ciency of GH, prolactin, and
TSH is associated with decreased LH and FSH gene expres-
sion [3] and low LH and FSH plasma levels [4]. This non-
allelic mutation, characterized by an absence of detectable Pit-
1 transcripts in developing pituitaries [5,6], was recently
shown to result from a defect in the gene encoding Prophet
of Pit-1 (Prop-1) [7], a novel pituitary-speci¢c paired-like ho-
meodomain transcription factor [8].
In humans, numerous Pit-1 gene mutations have been de-
scribed in patients with familial or sporadic CPHD [9]. Just
recently, during the course of this study, four Prop-1 muta-
tions have been reported in patients with CPHD [10,11]. To
facilitate screening for mutations of Prop-1 in CPHD and to
further test the involvement of this transcription factor in this
disease phenotype, we have isolated the human ortholog of
mouse Prop-1 cDNA, determined the exon/intron organiza-
tion and chromosomal localization of the human gene, and
investigated three candidate CPHD families.
2. Materials and methods
2.1. Cloning and sequencing of the human Prop-1 cDNA and genomic
DNA
To isolate the human (h) ortholog of mouse Prop-1 cDNA, cross-
species PCR was performed using primers chosen from the mouse
Prop-1 cDNA sequence (P1: 5P-CCGCCACCGCACCACCTT-
CAACCCA-3P, and P2: 5P-GGGGGCTGGGTGCAAGGTGGGG-
TAC-3P) with human genomic DNA as a template; as a control,
similar experiments were carried out with mouse genomic DNA. Se-
quencing of the human PCR product led to the characterization of a
397-bp fragment of the hProp-1 coding sequence. Based on the latter
sequence, both 5P and 3P portions of the hProp-1 cDNA sequence
were obtained by RACE with the use of human pituitary 5P- and
3P-RACE-Ready cDNA (Clontech).
To characterize the intron/exon organization of the human Prop-1
gene, human genomic DNA was subjected to PCR ampli¢cation in
several overlapping fragments using primers designed from the human
full-length cDNA coding sequence. The resulting PCR products were
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cloned into PCR 2.1 Topo vector (Invitrogen) prior to sequencing. All
sequences were determined on both strands.
2.2. Chromosomal localization of the human Prop-1 gene
The chromosomal localization of the human Prop-1 gene was ¢rst
determined by using the PCRable DNA MSC human/rodent somatic
cell hybrid mapping panel (Quantum) as template. PCR was per-
formed with primers located in intron II (5P-AAAGACTGGAGCA-
GCACAGGACGCA-3P, 5P-GCAAGTAAGAAGTGTCAGCTTCC-
AC-3P). Ampli¢cation products were analyzed by electrophoresis on
a 1% agarose gel stained with ethidium bromide.
Further localization was achieved by FISH analysis of human chro-
mosome spreads, using a biotin-labeled plasmid clone containing
3.6 kb of the genomic Prop-1 sequence, as described [12].
2.3. Subjects
Three CPHD families were investigated. One originates from Tuni-
sia (family A), the second from Egypt (family B), and the remaining
one from Turkey (family C). All a¡ected individuals were born to
consanguineous unions. They presented with severe growth retarda-
tion (below 35 S.D. in height) associated with clinical evidence of
hypogonadism (micropenis and microorchidy in patients AII1 and
AII2; infantile gonads with pubertal delay at 15 and 17 years old in
patients BII2 and BIII1, respectively; pubertal delay in patients BIII2,
CII1 and CII2), and pituitary hypoplasia in patients AII1, AII2, BII3,
CII1 and CII2. Endocrinological investigations performed in families
A and C revealed the existence of CPHD involving GH, TSH, pro-
lactin, FSH and LH, the cortisol levels being in the normal range. A
combined GH, TSH, FSH and LH de¢ciency was documented in the
patients belonging to family B.
2.4. Prop-1 mutation screening
Genomic DNA was isolated from blood samples obtained from
each individual using standard techniques. Screening for mutations
was carried out by direct sequencing of PCR products ampli¢ed
from genomic DNA, using three primer sets (F1: 5P-GAGCTGCG-
GAAGCAGAGAAATCTCA-3P and R1: 5P-AGAGGTAACTG-
TCTCACATCCCCAC-3P ; F2: 5P-AAAGACTGGAGCAGCACAG-
GACGCA-3P and R2: 5P-GCAAGTAAGAAGTGTCAGCTTCCAC-
3P ; F3: 5P-CTCTTGTCATTGGAGTAGGGTGTCA-3P and R3: 5P-
CAGACTTCCTCCACTAATCACCCCA-3P) £anking the three cod-
ing exons of Prop-1.
2.5. Site-directed mutagenesis and splicing assays
A PCR ampli¢cation product encompassing the whole Prop-1 cod-
ing sequence was generated from control genomic DNA using a for-
ward primer located 64 bp upstream the translation start site and a
reverse primer located 186 bp downstream of the termination codon.
This product was subcloned into the SV40 promoter-based expression
vector pECE [13] and subjected to site-directed mutagenesis using the
QuikChange kit (Stratagene) with oligonucleotides designed to intro-
duce the A-to-T substitution found in family C.
Transient expression of the wild-type and mutant constructs in
COS-7 cells was performed as described elsewhere [14]. Approxi-
mately 24 h after transfection, total RNA was isolated and reverse-
transcription-primed PCR (RT-PCR) was performed. The e¡ect of the
splice-acceptor-site mutation was studied by use of a sense primer
located on exon 2 (5P-AGTGCAGTTGGAACAGCTGGAGTCA-
3P) and an antisense primer located on exon 3 (5P-CAGACTTCCTC-
CACTAATCACCCCA-3P). Aliquots of RT-PCR from cells trans-
fected with the wild-type and mutant constructs were analyzed by
electrophoresis on a 1% agarose gel.
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Fig. 1. Human Prop-1 cDNA coding sequence and genomic struc-
ture. a: Alignment of human (h) and mouse (m) Prop-1 cDNA and
amino acid (Prot.) sequences, and location of exon-intron bounda-
ries. The predicted amino acid sequence of human and mouse Prop-
1 is indicated by one-letter abbreviations below the human and
above the mouse cDNA sequence, respectively. Nucleotides and
amino acids are numbered on the right (nucleotide +1 corresponds
to A of the ATG translation start codon). Identical amino acid resi-
dues are boxed, and gaps introduced to optimize the alignment are
indicated by dashes. The shaded sequence encodes the homeodo-
main. The dark triangles indicate the location of the two introns. b:
Schematic representation of the genomic organization of the human
Prop-1 gene. Exons are indicated by ¢lled or empty boxes (trans-
lated or untranslated sequences, respectively). The exons and introns
are drawn to scale; the exact sizes are given for the introns.
Table 1
Splice donor and acceptor sites and sizes of exons of the human Prop-1 gene
Exon Splice donor and acceptor sites
No. Size (bp) 3P acceptor 5P donor
1 s 418 GGTGGgtragtgacc....
2 233 ....ccgttctcagACTCG TCCAGgtgatgctcc....
3 s 812 ....cccttctcagGTCTG
Consensus
(c/t)ncag gtragt
Exon sequences are in uppercase letters; intron sequences are in lowercase letters, with the conforming 5P gt and 3P ag sequences in bold letters.
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3. Results
3.1. Isolation of the human cDNA and gene encoding Prop-1
We performed cross-species PCR using primers (P1^P2)
chosen from the mouse Prop-1 cDNA sequence with human
or mouse genomic DNA as a template. This gave rise to PCR
products the sizes of which were similar in both species and
larger than expected for coding sequence, a result pointing to
the presence of an intronic sequence. New PCR primers were
subsequently used in 5P- and 3P-RACE experiments on human
pituitary cDNA. This procedure led to the characterization of
the full-length human Prop-1 coding sequence together with
parts of the 5P- and 3P-untranslated regions (UTR) (GenBank
accession number AF076215). While writing these data, this
sequence was not present in any of the publicly available
sequence databases. The 5P-UTR sequence includes 309 bp
upstream of the translation start site which belongs to a
good Kozak consensus sequence (5P-CGAGCCATGG-3P)
[15]. 3P-RACE led to the identi¢cation of 473 nucleotides after
the termination codon. The human coding cDNA sequence is
presented in Fig. 1a; when compared with the mouse Prop-1
coding sequence [7], the human sequence was found to be
highly conserved, demonstrating that this cDNA is indeed
the human ortholog of the mouse Prop-1 cDNA: overall,
the human and mouse coding sequences are 678 bp and 669
bp long, respectively; they are 78% identical at the nucleotide
level and predict proteins that are 73% identical. As expected,
maximum of identity was observed in the region encoding the
homeodomain, the human sequence being 91% identical to the
mouse Prop-1 sequence at the cDNA level and 93% identical
at the protein level.
Human Prop-1 gene (Fig. 1b) is composed of at least 3
exons and 2 introns covering less than 4 kb of genomic
DNA which was extensively sequenced (GenBank accession
number AF076214). Sequences at the exon boundaries, as well
as exon sizes are given in Table 1.
3.2. Chromosomal localization of the human Prop-1 gene
A primer set was used to screen a panel of 24 hybrid so-
matic cell lines (human/rodent) by PCR, each of them retain-
ing one of the 24 human chromosomes. An ampli¢cation
product of expected size and sequence was detected in only
one hybrid cell line, demonstrating the location of the human
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Fig. 2. FISH mapping the human Prop-1 gene. A speci¢c signal is
seen at 5q35 on both copies of chromosome 5 (arrowheads).
Fig. 3. Mutation analysis in families with CPHD. a: Genealogical trees of families A, B and C with CPHD. A¡ected individuals are shown as
¢lled-in symbols. Consanguinity was documented in all families. b: Sequence chromatograms of a¡ected individuals from families A (AII1),
B (BII2) and C (CII1) (top), and control subjects (bottom). Mutations are encircled.
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Prop-1 gene on chromosome 5 (data not shown). The gene
was sublocalized by £uorescence in situ hybridization. Spots
of speci¢c hybridization were observed on metaphase spreads
at band q35 (Fig. 2).
3.3. Mutation analysis in CPHD families
In family A (Fig. 3a), both patients (AII1 and AII2) dis-
played a homozygous C-to-T transition (C217T) at codon 73
in exon 2 (Fig. 3b); this nucleotide change predicts a missense
mutation (R73C) located in the N-terminal region of the ho-
meodomain. As expected for recessively inherited diseases oc-
curring in consanguineous families, both parents (AI1 and
AI2) were found to be heterozygous for the mutant allele.
An intronic point mutation (A-to-T substitution) involving
the last dinucleotide of the splice-acceptor site preceding exon
3 was identi¢ed in family B (Fig. 3a and b). The four patients
(BII2, BII3, BIII1 and BIII2) were found to be homozygous
for this mutation, whereas one healthy sibling (BII1) was het-
erozygous, a result consistent with the consanguinity docu-
mented in this family. To determine the consequences of
this splice-acceptor-site mutation on the processing of Prop-
1 transcripts, COS-7 cells were transfected with normal or
mutant human Prop-1 genes. RT-PCR of RNA isolated
from cells transfected with the wild-type construct yielded a
634-bp amplicon consistent with normal splicing of intron II
(Fig. 4a and b). In contrast, RT-PCR of RNA isolated from
cells transfected with the mutant construct produced large
amounts of a larger PCR product (1690 bp) together with a
weakly expressed species (622 bp) (Fig. 4a). Sequence deter-
mination of these products revealed that the mutation abol-
ishes normal splicing: it generates a major transcript (1690
bp) retaining intron II, and a minor transcript (622 bp) that
results from the utilization of a cryptic splice site within exon
3 (5P-TCTGGTTCCAG-3P), thereby causing the loss of the
¢rst 12 nucleotides of this exon (Fig. 4b).
In family C (Fig. 3a), a 2-bp deletion (del nt 296^297) was
detected in exon 2 (Fig. 3b). This causes a frameshift, which
predicts a premature TGA stop codon at position 109. Sim-
ilarly, in this consanguineous family, both patients (CII1 and
CII3) were found to be homozygous for this mutation, where-
as both parents (CI1, CI2) and two healthy siblings (CII4 and
CII5) were heterozygous, the healthy brother (CII2) carrying
two normal Prop-1 alleles.
To further test whether the three mutations are responsible
for the CPHD phenotype, 21 unrelated control individuals
were screened for these Prop-1 nucleotide variations. None
of their 42 chromosomes contained such mutations. However,
in the course of this study, we detected three intragenic poly-
morphic sites. Two of them are transcribed: one is a synon-
ymous substitution located at nucleotide 27 of the coding
sequence (codon 9) in the ¢rst exon (GCTCGCC); the other
one, which is located in exon 3 outside the homeodomain, is a
G-to-A transition at nucleotide 424 resulting in the A142T
substitution. The remaining polymorphic site involves the
third nucleotide of intron I that can be either an adenine or
a guanine residue. The frequency of these Prop-1 variants
among the 42 control chromosomes studied is provided in
Table 2. In the control population, the thymine residue at
codon 9 was always associated with an adenine residue at
the third nucleotide of intron I (Table 2), a result demonstrat-
ing a complete linkage disequilibrium between these two intra-
genic loci.
4. Discussion
We have cloned, mapped, determined the structure for, and
sought CPHD-associated mutations in the human gene encod-
ing Prop-1, a novel pituitary-speci¢c transcription factor re-
cently characterized in mice [7]. Two nucleotide variations
were identi¢ed in the human Prop-1 coding sequence of un-
related controls, one leading to an amino acid substitution at
codon 142 (alanine or threonine); this amino acid change,
which is located outside the homeodomain, is considered as
a polymorphism, since it was present in 19% of the 42 chro-
mosomes studied. The human amino acid sequence concurs
with a recent study in which an alanine residue was present at
position 142 [10], whereas the reported mouse Prop-1 se-
quence contained a threonine residue at this position [7], an
observation further supporting that residue 142 is indeed pol-
ymorphic. The human gene spans a genomic fragment of
about 4 kb of chromosome 5 in a region (q35) syntenic to
the mouse chromosome 11 which was shown to contain the
Prop-1 gene [7,16]. In comparing the human Prop-1 cDNA
and genomic sequences, we were able to determine the intron-
exon boundaries ; the human Prop-1 gene includes three trans-
FEBS 20993 27-10-98 Cyaan Magenta Geel Zwart
Fig. 4. Functional consequences of the A-to-T substitution identi¢ed
in Family B on Prop-1 RNA splicing. a: RT-PCR ampli¢cation of
RNA from COS-7 cells transfected with the normal (lane N) or mu-
tant (lane Mut) Prop-1 gene. Lane L: Molecular size ladder (Smart
Ladder Eurogentec). b: Schematic representations of the splicing
mechanisms leading to normal (top) and abnormal (bottom) Prop-1
transcripts. Normal splicing (N) of intron II results in the genera-
tion of a 634-bp product, whereas the T-to-C substitution of the
last dinucleotide of intron II (vertical arrow) results in two abnor-
mal Prop-1 messengers (Mut), the major one (1690 bp) retaining the
intronic sequence, and the minor one (622 bp) resulting from the
use of a cryptic splice-acceptor site located in exon 3 (vertical dotted
line within exon 3).
Table 2
Frequency of Prop-1 variants in a control population
Location Nucleotide changea Amino acid change Allele frequency in control population
Exon 1 TCC at nt 27 A9A 20/42 chromosomes (47.6%)
Intron I ACG at nt 109+3 ^ 20/42 chromosomes (47.6%)
Exon 3 GCA at nt 424 A142T 8/42 chromosomes (19%)
aNucleotide numbering refers to the adenine residue of the ATG translation start codon as nucleotide number one.
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lated exons, each intron-exon boundary containing the gt-ag
consensus sequences for eukaryotic donor and acceptor splice
sites [17].
The description of a Prop-1 missense mutation in the Ames
dwarf mouse strain [7] characterized by CPHD associated
with hypoplastic anterior pituitary, prompted us to examine
the human ortholog as a CPHD candidate gene. Eight pa-
tients belonging to three independent families were examined.
Since all a¡ected individuals were born to consanguineous
unions and parents showed no symptoms, an autosomal re-
cessive mode of inheritance was considered. We found one
missense mutation, one frameshift mutation, and one splice-
site mutation, all highly likely to be responsible for the disease
phenotype. Indeed, all three mutations, which were absent
from 42 control chromosomes, are located in the gene frag-
ment encoding the homeodomain of the Prop-1 protein. Their
segregation with a¡ection status is complete in each family, in
keeping with the recessive transmission of the disease pheno-
type. The R73C missense mutation replaces a charged residue
by a neutral amino acid in a region highly conserved among
all members of the paired-like class of homeodomains. More-
over, this arginine residue, which is invariant in all these pro-
teins, is conserved in 95% of the more than 400 homeodomain
proteins so far identi¢ed [8,18]. As this amino acid substitu-
tion results from a C-to-T transition at a CpG doublet, it may
correspond to a mutational hot spot, a hypothesis that could
be tested by the molecular study of additional CPHD cases. It
is striking to note that the 2-bp deletion identi¢ed in one
family involves a dinucleotide (AG) that belongs to a series
of three tandem repeats; since the same molecular defect was
identi¢ed in other CPHD families [10,11], it is highly likely to
represent a mutational hot spot, such repeats, like classical
microsatellite loci, being prone to mutation by slipped strand
mispairing. To address this question, the Prop-1 intragenic
polymorphic sites identi¢ed in this study may be compared
among those families to determine whether the mutation is
recurrent or results from a founder e¡ect. The nucleotide var-
iation identi¢ed in our third CPHD kindred is a splice-site
mutation in the conserved 3P region of the intron preceding
exon 3. In vitro splicing assays indeed demonstrated that the
latter mutation generates two abnormal Prop-1 transcripts :
the major one, which retains intron II, would result in a se-
verely truncated protein with a deletion of about 50% of the
Prop-1 protein including a large fragment of the homeodo-
main; the minor abnormal Prop-1 transcript is generated
through the use of a cryptic splice site located in exon 3
[19]; if translated, it would result in the deletion of 4 residues
of the homeodomain, two of which being invariant in more
than 95% of all homeoproteins so far identi¢ed [8,18]. Alto-
gether, these data strongly suggest that this mutation substan-
tially alters the function of the Prop-1 gene.
A total of 6 di¡erent Prop-1 mutations have been identi¢ed
in the CPHD families so far investigated ([10,11], and this
study). Strikingly, all these mutations are clustered in the
gene fragment encoding a key functional domain, the homeo-
domain. These patients displayed a disease phenotype similar
to that of patients with a Pit-1 defect. However, Prop-1-de¢-
cient patients are also gonadotropin de¢cient; Prop-1, which
is known to be essential for the determination of the somato-
troph, lactotroph, and thyreotroph Pit-1-dependent lineages
[5,20], therefore appears to be critical to the proper develop-
ment of gonadotrophs.
The genetic heterogeneity of CPHD in humans is demon-
strated by the existence of deleterious mutations in Pit-1 and
Prop-1; it is likely that the recent description of CPHD phe-
notypes in murine strains generated by targeted disruption of
other pituitary-speci¢c transcription factors [21^25] will pro-
vide a basis for the molecular characterization of other types
of combined hormone pituitary de¢ciencies in humans. This
was recently illustrated by the association of forebrain midline
defects with pituitary dysplasia in Hesx-1 null mutant mice, a
result that led to the identi¢cation of Hesx-1 mutations in
patients with septo-optic dysplasia [26]. Such studies will
also contribute to elucidate the hierarchy of genetic factors
involved in pituitary development.
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